| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.1 | — |
| Gross profit | 0.0 | — |
| Profit before tax | -4.9 | -15.7 |
| Net income | -4.9 | -15.7 |
| EPS (diluted, $ a share) | $-0.14 | $-8.20 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Gross margin | 11.9% |
|---|
10-Q filed with the SEC, NASDAQ: DWTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Dogwood Therapeutics, Inc.: key numbers
- Share price
- $1.08Close, Nov 17
- Market cap
- $41.3M
- Shares outstanding
- 38.23MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Dogwood Therapeutics, Inc.
All →Dogwood Therapeutics Financial Results
Dogwood Therapeutics reported third quarter 2026 financial results, highlighting the completion of its Halneuron Phase 2b trial for chemotherapy-induced neuropathic pain with top-line results expected in November 2026. The company also closed a $5 million private placement with Sealbond Limited to fund Phase 3 preparatory activities, extending its cash runway into the first quarter of 2027.
- Term
- 3 months
“With results from the recently completed Phase 2b CINP study to be reported in November, we believe that if successful, Halneuron® could represent the first new therapeutic agent for millions of CINP patients in the US and tens of millions of CINP patients across the globe.”
Greg Duncan, Chief Executive Officer of Dogwood Therapeutics
Dogwood Therapeutics Capital Raise of $5M
Dogwood Therapeutics entered into a subscription agreement to sell 4,098,360 shares of common stock to its largest shareholder, Sealbond Limited (a subsidiary of CK Life Sciences), in a $5 million private placement. The proceeds will be used to fund Phase 3 preparatory activities for Halneuron® and extend the company's operational runway through March 2027.
- Value
- $5M
- Counterparty
- Sealbond Limited